Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexmedetomidine + bupivacaine is a combination of a highly selective alpha-2 adrenergic receptor agonist and a local anesthetic, being studied as a spinal anesthesia regimen. Dexmedetomidine acts as an adjuvant to enhance the sensory and motor block of bupivacaine while prolonging postoperative analgesia. This specific formulation and study were conducted at Hospital Central Dr. Luis Ortega for patients undergoing lower abdominal surgeries. The combination is administered subarachnoideally (intrathecally) to provide effective anesthesia and analgesia without significant hemodynamic compromise.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexmedetomidine + bupivacaine (Hospital Central Dr. Luis Ortega).